

## Blisibimod

Cat. No.:	HY-P99482
CAS No.:	1236126-45-6
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Blisibimod (A 623) is a potent and selective tetravalent inhibitor of B-cell activating factor (BAFF). Blisibimod can be used for the research of systemic lupus erythematosus (SLE) <sup>[1][2]</sup> .
In Vitro	Blisibimod blocks with high affinity all three forms of BAFF <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Merrill JT, et, al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis*. 2018 Jun;77(6):883-889.
- [2]. Lenert A, et, al. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. *Drug Des Devel Ther*. 2017 Mar 13;11:747-757.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA